SCHEMBL4127749

SCHEMBL4127749

CCCOc1cc2ccccc2cc1/C=C1/SC(Nc2ccc(CC(=O)O)cc2)=NC1=O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.46
MEN1 O00255 4/20 0.46
NPC1 O15118 2/20 0.42
PTP4A3 O75365 3/20 0.39
HPGD P15428 3/20 0.38
MAPT P10636 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
IKBKB O14920 1/20 0.37
KDM4E B2RXH2 3/20 0.37
NPSR1 Q6W5P4 1/20 0.37
POLB P06746 1/20 0.37
PDE4B Q07343 3/20 0.36
NR1H4 Q96RI1 2/20 0.36
ALDH1A1 P00352 3/20 0.35
GAA P10253 2/20 0.35
LMNA P02545 2/20 0.35
RECQL P46063 1/20 0.35
RAB9A P51151 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4127754 1.00 KMT2A (0.46) KMT2AMEN1NPC1PTP4A3HPGD
SCHEMBL4128848 0.91 MEN1 (0.43) KMT2AMEN1NPC1HPGDMAPT
SCHEMBL4128846 0.91 MEN1 (0.43) KMT2AMEN1NPC1HPGDMAPT
SCHEMBL4125736 0.90 PTP4A3 (0.50) KMT2AMEN1PTP4A3TDP1IKBKB
SCHEMBL4125733 0.90 PTP4A3 (0.50) KMT2AMEN1PTP4A3TDP1IKBKB
SCHEMBL4128926 0.88 S1PR1 (0.43) KMT2AMEN1NPC1PTP4A3HPGD
SCHEMBL4128924 0.88 S1PR1 (0.43) KMT2AMEN1NPC1PTP4A3HPGD
SCHEMBL4131686 0.87 MEN1 (0.45) KMT2AMEN1PTP4A3TDP1POLB
SCHEMBL4131690 0.87 MEN1 (0.45) KMT2AMEN1PTP4A3TDP1POLB
SCHEMBL4127646 0.86 CHEK1 (0.40) KMT2AMEN1NPC1PTP4A3HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ KMT2A 2895/4885MEN1 4075/4885NPC1 2256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.